ACADIA Pharmaceuticals ACAD
$17.11 −$0.48 (-2.73%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $17.12 +0.06%
Open$17.47
Prev close$17.59
Day range$17.05 – $17.79
Volume1.90M
Market cap$2.96B
P/E (TTM)8.1
Dividend yield–
ACAD Stock News
Headlines matching ACADIA Pharmaceuticals or the ACAD ticker, most recent first.
- CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $36
- A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $31 to $36
- Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX) Positive
- Analysts' Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)
- Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $26
- BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $31 Positive
- A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $38
- RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $37 Positive
- Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38 Positive
- A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $40
- BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $36
- UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $49
- UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $49 Positive
- Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41 Positive
- Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $39 Positive
No comments yet — be the first to weigh in on ACAD.
Sign in to join the discussion.